Clinical Trial Update: UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial of UCAR T-cell therapy targeting CD19/BCMA for relapsed/refractory Myasthenia gravis. The study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• UCAR T-cell therapy targeting CD19/BCMA

Snippet

Sponsor: Zhejiang University | Conditions: Myasthenia Gravis | EARLY_Phase 1 | Status: NOT_YET_RECRUITING